Glycogen synthase kinase 3beta contributes to proliferation of arterial smooth muscle cells in pulmonary hypertension

PLoS ONE

Volumn 6, Issue 4, 2011, Pages

  Sklepkiewicz, Piotr ^a   Schermuly, Ralph Theo ^a   Tian, Xia ^a   Ghofrani, Hossein Ardeschir ^a   Weissmann, Norbert ^a   Sedding, Daniel ^a   Kashour, Tarek ^b   Seeger, Werner ^a   Grimminger, Friedrich ^a   Pullamsetti, Soni Savai ^a  

^a UNIVERSITY HOSPITAL GIESSEN   (Germany)

^b KING FAHAD MEDICAL CITY   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOGEN SYNTHASE KINASE 3BETA; MITOGEN ACTIVATED PROTEIN KINASE; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; PRIMER DNA; WNT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AXIN1 GENE; CELL PROLIFERATION; CONTROLLED STUDY; FRIZZLED RECEPTOR 1 GENE; FRIZZLED RECEPTOR 2 GENE; GENE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MALE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PULMONARY ARTERIAL SMOOTH MUSCLE CELL; PULMONARY HYPERTENSION; RAT; SECRETED FRIZZLED RELATED PROTEIN 1 GENE; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; UPREGULATION; WNT1 GENE; WNT3A GENE; WNT5A GENE; ANIMAL; ARTERY; CELL CULTURE; DISEASE MODEL; ENZYMOLOGY; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; MOLECULAR CLONING; MUTAGENESIS; NUCLEOTIDE SEQUENCE; PATHOLOGY; PHOSPHORYLATION; POLYMERASE CHAIN REACTION; VASCULAR SMOOTH MUSCLE; WESTERN BLOTTING;

RATTUS;

ANIMALS; ARTERIES; BASE SEQUENCE; BLOTTING, WESTERN; CELL PROLIFERATION; CELLS, CULTURED; CLONING, MOLECULAR; DISEASE MODELS, ANIMAL; DNA PRIMERS; GLYCOGEN SYNTHASE KINASE 3; HUMANS; HYPERTENSION, PULMONARY; IMMUNOHISTOCHEMISTRY; MALE; MUSCLE, SMOOTH, VASCULAR; MUTAGENESIS; PHOSPHORYLATION; POLYMERASE CHAIN REACTION; RATS; WNT PROTEINS;

EID: 79955157410     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0018883     Document Type: Article

References (49)

1. Rubin LJ, (2006) Pulmonary arterial hypertension. Proc Am Thorac Soc 3: 111-115.
2. D'Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, et al. (1991) Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 115: 343-349.
3. Humbert M, Morrell NW, Archer SL, Stenmark KR, MacLean MR, et al. (2004) Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 43: 13S-24S.
4. Rabinovitch M, (2008) Molecular pathogenesis of pulmonary arterial hypertension. J Clin Invest 118: 2372-2379.
5. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, et al. (2002) Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346: 896-903.
6. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, et al. (1996) A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 334: 296-302.
7. Galie N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, et al. (2005) Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 353: 2148-2157.
8. Schermuly RT, Dony E, Ghofrani HA, Pullamsetti S, Savai R, et al. (2005) Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 115: 2811-2821.
9. Perros F, Montani D, Dorfmuller P, Durand-Gasselin I, Tcherakian C, et al. (2008) Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 178: 81-88.
10. Merklinger SL, Jones PL, Martinez EC, Rabinovitch M, (2005) Epidermal growth factor receptor blockade mediates smooth muscle cell apoptosis and improves survival in rats with pulmonary hypertension. Circulation 112: 423-431.
11. Wedgwood S, Devol JM, Grobe A, Benavidez E, Azakie A, et al. (2007) Fibroblast growth factor-2 expression is altered in lambs with increased pulmonary blood flow and pulmonary hypertension. Pediatr Res 61: 32-36.
12. McMurtry MS, Archer SL, Altieri DC, Bonnet S, Haromy A, et al. (2005) Gene therapy targeting survivin selectively induces pulmonary vascular apoptosis and reverses pulmonary arterial hypertension. J Clin Invest 115: 1479-1491.
13. Klein M, Schermuly RT, Ellinghaus P, Milting H, Riedl B, et al. (2008) Combined tyrosine and serine/threonine kinase inhibition by sorafenib prevents progression of experimental pulmonary hypertension and myocardial remodeling. Circulation 118: 2081-2090.
14. Grimes CA, Jope RS, (2001) The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Prog Neurobiol 65: 391-426.
15. Doble BW, Woodgett JR, (2003) GSK-3: tricks of the trade for a multi-tasking kinase. J Cell Sci 116: 1175-1186.
16. van Weeren PC, de Bruyn KM, de Vries-Smits AM, van Lint J, Burgering BM, (1998) Essential role for protein kinase B (PKB) in insulin-induced glycogen synthase kinase 3 inactivation. Characterization of dominant-negative mutant of PKB. J Biol Chem 273: 13150-13156.
17. Pap M, Cooper GM, (1998) Role of glycogen synthase kinase-3 in the phosphatidylinositol 3-Kinase/Akt cell survival pathway. J Biol Chem 273: 19929-19932.
18. Sakanaka C, Weiss JB, Williams LT, (1998) Bridging of beta-catenin and glycogen synthase kinase-3beta by axin and inhibition of beta-catenin-mediated transcription. Proc Natl Acad Sci U S A 95: 3020-3023.
19. Fiol CJ, Williams JS, Chou CH, Wang QM, Roach PJ, et al. (1994) A secondary phosphorylation of CREB341 at Ser129 is required for the cAMP-mediated control of gene expression. A role for glycogen synthase kinase-3 in the control of gene expression. J Biol Chem 269: 32187-32193.
20. Welsh GI, Miller CM, Loughlin AJ, Price NT, Proud CG, (1998) Regulation of eukaryotic initiation factor eIF2B: glycogen synthase kinase-3 phosphorylates a conserved serine which undergoes dephosphorylation in response to insulin. FEBS Lett 421: 125-130.
21. Morisco C, Seta K, Hardt SE, Lee Y, Vatner SF, et al. (2001) Glycogen synthase kinase 3beta regulates GATA4 in cardiac myocytes. J Biol Chem 276: 28586-28597.
22. Shakoori A, Ougolkov A, Yu ZW, Zhang B, Modarressi MH, et al. (2005) Deregulated GSK3beta activity in colorectal cancer: its association with tumor cell survival and proliferation. Biochem Biophys Res Commun 334: 1365-1373.
23. Wang X, Xiao Y, Mou Y, Zhao Y, Blankesteijn WM, et al. (2002) A role for the beta-catenin/T-cell factor signaling cascade in vascular remodeling. Circ Res 90: 340-347.
24. Schermuly RT, Pullamsetti SS, Kwapiszewska G, Dumitrascu R, Tian X, et al. (2007) Phosphodiesterase 1 upregulation in pulmonary arterial hypertension: target for reverse-remodeling therapy. Circulation 115: 2331-2339.
25. Lai YJ, Pullamsetti SS, Dony E, Weissmann N, Butrous G, et al. (2008) Role of the prostanoid EP4 receptor in iloprost-mediated vasodilatation in pulmonary hypertension. Am J Respir Crit Care Med 178: 188-196.
26. Pullamsetti S, Krick S, Yilmaz H, Ghofrani HA, Schudt C, et al. (2005) Inhaled tolafentrine reverses pulmonary vascular remodeling via inhibition of smooth muscle cell migration. Respir Res 6: 128.
27. Pullamsetti S, Kiss L, Ghofrani HA, Voswinckel R, Haredza P, et al. (2005) Increased levels and reduced catabolism of asymmetric and symmetric dimethylarginines in pulmonary hypertension. FASEB J 19: 1175-1177.
28. Savai R, Schermuly RT, Voswinckel R, Renigunta A, Reichmann B, et al. (2005) HIF-1alpha attenuates tumor growth in spite of augmented vascularization in an A549 adenocarcinoma mouse model. Int J Oncol 27: 393-400.
29. Arciniegas E, Frid MG, Douglas IS, Stenmark KR, (2007) Perspectives on endothelial-to-mesenchymal transition: potential contribution to vascular remodeling in chronic pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 293: L1-8.
30. Bentley JK, Deng H, Linn MJ, Lei J, Dokshin GA, et al. (2009) Airway smooth muscle hyperplasia and hypertrophy correlate with glycogen synthase kinase-3(beta) phosphorylation in a mouse model of asthma. Am J Physiol Lung Cell Mol Physiol 296: L176-184.
31. Chilosi M, Poletti V, Zamo A, Lestani M, Montagna L, et al. (2003) Aberrant Wnt/beta-catenin pathway activation in idiopathic pulmonary fibrosis. Am J Pathol 162: 1495-1502.
32. Goode N, Hughes K, Woodgett JR, Parker PJ, (1992) Differential regulation of glycogen synthase kinase-3 beta by protein kinase C isotypes. J Biol Chem 267: 16878-16882.
33. Ali A, Hoeflich KP, Woodgett JR, (2001) Glycogen synthase kinase-3: properties, functions, and regulation. Chem Rev 101: 2527-2540.
34. George SJ, Beeching CA, (2006) Cadherin:catenin complex: a novel regulator of vascular smooth muscle cell behaviour. Atherosclerosis 188: 1-11.
35. Mikels AJ, Nusse R, (2006) Purified Wnt5a protein activates or inhibits beta-catenin-TCF signaling depending on receptor context. PLoS Biol 4: e115.
36. Miller JR, Hocking AM, Brown JD, Moon RT, (1999) Mechanism and function of signal transduction by the Wnt/beta-catenin and Wnt/Ca2+ pathways. Oncogene 18: 7860-7872.
37. Laumanns IP, Fink L, Wilhelm J, Wolff JC, Mitnacht-Kraus R, et al. (2009) The noncanonical WNT pathway is operative in idiopathic pulmonary arterial hypertension. Am J Respir Cell Mol Biol 40: 683-691.
38. Chen XY, Dun JN, Miao QF, Zhang YJ, (2009) Fasudil hydrochloride hydrate, a Rho-kinase inhibitor, suppresses 5-hydroxytryptamine-induced pulmonary artery smooth muscle cell proliferation via JNK and ERK1/2 pathway. Pharmacology 83: 67-79.
39. Li F, Xia W, Yuan S, Sun R, (2009) Acute inhibition of Rho-kinase attenuates pulmonary hypertension in patients with congenital heart disease. Pediatr Cardiol 30: 363-366.
40. Zhang S, Dong H, Rubin LJ, Yuan JX, (2007) Upregulation of Na+/Ca2+ exchanger contributes to the enhanced Ca2+ entry in pulmonary artery smooth muscle cells from patients with idiopathic pulmonary arterial hypertension. Am J Physiol Cell Physiol 292: C2297-2305.
41. Tsakiridis T, Tsiani E, Lekas P, Bergman A, Cherepanov V, et al. (2001) Insulin, insulin-like growth factor-I, and platelet-derived growth factor activate extracellular signal-regulated kinase by distinct pathways in muscle cells. Biochem Biophys Res Commun 288: 205-211.
42. Shin HS, Lee HJ, Nishida M, Lee MS, Tamura R, et al. (2003) Betacellulin and amphiregulin induce upregulation of cyclin D1 and DNA synthesis activity through differential signaling pathways in vascular smooth muscle cells. Circ Res 93: 302-310.
43. Fang X, Yu SX, Lu Y, Bast RC Jr, Woodgett JR, et al. (2000) Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A. Proc Natl Acad Sci U S A 97: 11960-11965.
44. Rubinfeld B, Albert I, Porfiri E, Fiol C, Munemitsu S, et al. (1996) Binding of GSK3beta to the APC-beta-catenin complex and regulation of complex assembly. Science 272: 1023-1026.
45. de Jesus Perez VA, Alastalo TP, Wu JC, Axelrod JD, Cooke JP, et al. (2009) Bone morphogenetic protein 2 induces pulmonary angiogenesis via Wnt-beta-catenin and Wnt-RhoA-Rac1 pathways. J Cell Biol 184: 83-99.
46. Diehl JA, Cheng M, Roussel MF, Sherr CJ, (1998) Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev 12: 3499-3511.
47. Wang Q, Zhou Y, Wang X, Evers BM, (2006) Glycogen synthase kinase-3 is a negative regulator of extracellular signal-regulated kinase. Oncogene 25: 43-50.
48. Bonnet S, Paulin R, Sutendra G, Dromparis P, Roy M, et al. (2009) Dehydroepiandrosterone reverses systemic vascular remodeling through the inhibition of the Akt/GSK3-{beta}/NFAT axis. Circulation 120: 1231-1240.
49. Park KW, Yang HM, Youn SW, Yang HJ, Chae IH, et al. (2003) Constitutively active glycogen synthase kinase-3beta gene transfer sustains apoptosis, inhibits proliferation of vascular smooth muscle cells, and reduces neointima formation after balloon injury in rats. Arterioscler Thromb Vasc Biol 23: 1364-1369.